IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization
- PMID: 33622713
- DOI: 10.1158/2326-6066.CIR-20-0226
IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization
Abstract
In addition to immunosuppression, it is generally accepted that myeloid-derived suppressor cells (MDSC) also support tumor angiogenesis. The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) has been implicated in promoting neovascularization through its positioning as a key regulatory node between the inflammatory cytokines IFNγ and IL6. Here, we report that within the heterogeneous expanse of Gr-1+ MDSCs, both IDO1 expression and the ability to elicit neovascularization in vivo were associated with a minor subset of autofluorescent, CD11blo cells. IDO1 expression was further restricted to a discrete, CD11c and asialo-GM1 double-positive subpopulation of these cells, designated here as IDVCs (IDO1-dependent vascularizing cells), due to the dominant role that IDO1 activity in these cells was found to play in promoting neovascularization. Mechanistically, the induction of IDO1 in IDVCs provided a negative-feedback constraint on the antiangiogenic effect of host IFNγ by intrinsically signaling for the production of IL6 through general control nonderepressible 2 (GCN2)-mediated activation of the integrated stress response. These findings reveal fundamental molecular and cellular insights into how IDO1 interfaces with the inflammatory milieu to promote neovascularization.
©2021 American Association for Cancer Research.
Similar articles
-
IDO1 is an Integral Mediator of Inflammatory Neovascularization.EBioMedicine. 2016 Dec;14:74-82. doi: 10.1016/j.ebiom.2016.11.013. Epub 2016 Nov 9. EBioMedicine. 2016. PMID: 27889479 Free PMC article.
-
Amino acid deprivation links BLIMP-1 to the immunomodulatory enzyme indoleamine 2,3-dioxygenase.J Immunol. 2009 Nov 1;183(9):5768-77. doi: 10.4049/jimmunol.0803480. Epub 2009 Oct 14. J Immunol. 2009. PMID: 19828629
-
IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation.Front Oncol. 2023 Apr 27;13:1165298. doi: 10.3389/fonc.2023.1165298. eCollection 2023. Front Oncol. 2023. PMID: 37182174 Free PMC article. Review.
-
Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans.PLoS One. 2010 Jul 28;5(7):e11825. doi: 10.1371/journal.pone.0011825. PLoS One. 2010. PMID: 20689575 Free PMC article.
-
Targeting the IDO1 pathway in cancer: from bench to bedside.J Hematol Oncol. 2018 Aug 2;11(1):100. doi: 10.1186/s13045-018-0644-y. J Hematol Oncol. 2018. PMID: 30068361 Free PMC article. Review.
Cited by
-
The significant role of amino acid metabolic reprogramming in cancer.Cell Commun Signal. 2024 Jul 29;22(1):380. doi: 10.1186/s12964-024-01760-1. Cell Commun Signal. 2024. PMID: 39069612 Free PMC article. Review.
-
Dynamic proteomic change of tumor and immune organs in an immune-competent hepatocellular carcinoma mouse model.Am J Cancer Res. 2022 Apr 15;12(4):1621-1634. eCollection 2022. Am J Cancer Res. 2022. PMID: 35530287 Free PMC article.
-
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.Front Immunol. 2021 Dec 6;12:789473. doi: 10.3389/fimmu.2021.789473. eCollection 2021. Front Immunol. 2021. PMID: 34938297 Free PMC article. No abstract available.
-
The role of the kynurenine pathway in cardiovascular disease.Front Cardiovasc Med. 2024 May 31;11:1406856. doi: 10.3389/fcvm.2024.1406856. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38883986 Free PMC article. Review.
-
Multiple Roles of the Stress Sensor GCN2 in Immune Cells.Int J Mol Sci. 2023 Feb 21;24(5):4285. doi: 10.3390/ijms24054285. Int J Mol Sci. 2023. PMID: 36901714 Free PMC article. Review.
References
-
- Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov. 2007;6:273–86.
-
- Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res. 2015;3:1–11.
-
- Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3–8.
-
- Johnson BW, Achyut BR, Fulzele S, Mondal AK, Kolhe R, Arbab AS. Delineating pro-angiogenic myeloid cells in cancer therapy. Int J Mol Sci. 2018;19:2565.
-
- Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65:10794–800.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials